- Cocrystal Pharma, Inc. announced the **closing of a registered direct offering** and concurrent private placement on **September 15, 2025**.  **[1412486_0001493152-25-013495_ex99-2.htm:0]** **[1412486_0001493152-25-013495_form8-k.htm:1]** 
- The company sold **2,764,710 shares of common stock** at a purchase price of **$1.70 per share**.  **[1412486_0001493152-25-013495_ex99-2.htm:0]** **[1412486_0001493152-25-013495_form8-k.htm:1]** 
- This offering generated approximately **$4.7 million in upfront gross proceeds** for the company.  **[1412486_0001493152-25-013495_ex99-2.htm:0]** **[1412486_0001493152-25-013495_ex99-2.htm:1]** **[1412486_0001493152-25-013495_form8-k.htm:1]** 
- In a concurrent private placement, unregistered warrants to purchase up to **5,529,420 shares of common stock** were issued at an exercise price of **$1.50 per share**, potentially yielding an additional **$8.3 million in gross proceeds** if fully exercised.  **[1412486_0001493152-25-013495_ex99-2.htm:0]** **[1412486_0001493152-25-013495_ex99-2.htm:1]** **[1412486_0001493152-25-013495_form8-k.htm:1]** 
- The net proceeds from the offering are intended for **working capital and general corporate purposes**, including the continued development of novel medicines.  **[1412486_0001493152-25-013495_ex99-2.htm:1]** **[1412486_0001493152-25-013495_form8-k.htm:1]**

Cocrystal Pharma Closes Registered Direct Offering and Private Placement

- Cocrystal Pharma, Inc. showcased its lead pan-viral protease inhibitor, **CDI-988**, at the **9th International Calicivirus Conference** held from **September 7–11, 2025**.  **[1412486_0001641172-25-027247_ex99-1.htm:0]** **[1412486_0001641172-25-027247_form8-k.htm:1]** 
- President and co-CEO Sam Lee, PhD, presented the **scientific foundation and clinical progress** of CDI-988, highlighting its potential as the **first oral antiviral in development for norovirus infection**.  **[1412486_0001641172-25-027247_ex99-1.htm:0]** 
- Key findings from the Phase 1 study demonstrated CDI-988's **favorable safety profile** in human intestinal tissue and **high exposure in the small intestine**.  **[1412486_0001641172-25-027247_ex99-1.htm:0]** 
- The company recently completed its Phase 1 study and received **FDA Investigation New Drug (IND) clearance** for the next study.  **[1412486_0001641172-25-027247_ex99-1.htm:0]** 
- Cocrystal also announced **FDA authorization to proceed with a Phase 1b human challenge study** for CDI-988 as a potential norovirus prophylaxis and treatment, which is expected to begin **before year end**.  **[1412486_0001641172-25-027247_ex99-1.htm:0]**

Cocrystal Pharma Showcases Norovirus Antiviral CDI-988 at International Conference

- Cocrystal Pharma, Inc. announced a registered direct offering of **2,764,710 shares** of common stock (or equivalents) at **$1.70 per share**, expected to generate approximately **$4.7 million** in gross proceeds.  **[1412486_0001641172-25-027246_ex99-1.htm:1]** 
- Concurrently, the company will issue unregistered warrants to purchase up to **5,529,420 shares** of common stock at an exercise price of **$1.50 per share**, with a potential to raise an additional **$8.3 million** if fully exercised.  **[1412486_0001641172-25-027246_ex99-1.htm:1]** 
- The offering is priced at-the-market under Nasdaq rules, and the closing is anticipated around **September 15, 2025**.  **[1412486_0001641172-25-027246_ex99-1.htm:1]** 
- The net proceeds from this offering are designated for **working capital and general corporate purposes**.  **[1412486_0001641172-25-027246_ex99-1.htm:1]**

Cocrystal Pharma, Inc. announces registered direct offering and concurrent private placement

- Cocrystal Pharma presented its lead pan-viral protease inhibitor, **CDI-988**, as a potential **first oral antiviral** for the prevention and treatment of norovirus infection at the 9th International Calicivirus Conference.  **[1412486_9461727e12424c7fa1b8aae3690efac0_0]** 
- The company recently completed a **Phase 1 study** for CDI-988, which demonstrated a **favorable safety and tolerability profile** with no serious adverse events.  **[1412486_9461727e12424c7fa1b8aae3690efac0_0]** 
- The **U.S. FDA** has granted **Investigation New Drug (IND) clearance** for the next study and authorized a **Phase 1b human challenge study** for CDI-988, which is expected to begin **before year-end 2025**.  **[1412486_9461727e12424c7fa1b8aae3690efac0_0]**

Cocrystal Pharma (COCP)